Tuesday, May 15, 2012

Study: Successful Tx of Pancreatic Pseudocysts and Acute Cholecystitis


AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis

Peer-Reviewed Paper Validates Promise of New Transenteric Therapy.

Full press release is below.
SOURCE: Xlumena, Inc

MOUNTAIN VIEW, Calif., May 15, 2012 /PRNewswire/ -- Xlumena, Inc. announces the publication of a scientific paper describing the first human study of the AXIOS™ Stent and Delivery System. The article, entitled "Clinical evaluation of a novel lumen-apposing metal stent for endosonography-guided pancreatic pseudocyst and gallbladder drainage" appeared in the April issue of Gastrointestinal Endoscopy – the leading journal for advances in endoscopy.
The research reports technical and clinical success using the AXIOS Stent to treat 15 pancreatic pseudocyst and 5 acute cholecystitis patients. All the pseudocysts and cholecystitis symptoms resolved and did not recur during the 9 month follow-up period. There were no complications during stent placement or removal.
Pancreatic pseudocysts are painful and potentially dangerous fluid-filled sacs most often resulting from pancreatitis. They can be treated surgically, percutaneously or endoscopically. Cholecystitis, or inflammation of the gallbladder, is usually alleviated by surgically removing the gallbladder. Patients who cannot undergo surgery have only the uncomfortable option of having a percutaneous (external) drain inserted into their gallbladder.
"This study demonstrates the promise of the AXIOS Stent," says Takao Itoi, MD of Tokyo Medical University Hospital and the paper's lead author. "We were able to successfully treat these very sick patients endoscopically and enable them to avoid more invasive procedures."
The stent provides a new approach for gallstone removal. "Two patients in the trial had gallstones. In one of these the stones came out on their own through the stent and in the other we were able to remove the stones. This is a unique and potentially clinically important development," adds Dr. Itoi.
Also interesting is that one cholecystitis patient in the study refuses to have the stent removed. "She had undergone frequent and repeated interventions for her cholecystitis symptoms without any lasting benefit. Since the stent was placed 18 months ago the symptoms have not returned and so the patient has insisted we leave the stent in place," says Dr. Itoi.
The stent is delivered under endoscopic guidance in four steps using a specially-designed catheter. All stents were successfully placed with no problems.
Kenneth Binmoeller, MD, a co-author, is the Medical Director of the Interventional Endoscopy Service (IES) at California Pacific Medical Center and Xlumena's Chief Medical Officer. "We saw no complications related to the stent in this study and it performed just as we had expected. The 10 mm stent opening provided effective drainage and remained patent throughout the study. Flanges on the ends of the stent held it in place. One stent placed into a pseudocyst did migrate into stomach, though this occurred after the pseudocyst had resolved."
Research on the use of the AXIOS Stent to treat cholecystitis has been on-going. A poster describing the successful treatment of 11 patients will be reported at the upcoming DDW 2012 meeting in San Diego. As with the current study, once the stent was placed the patients had immediate relief of their cholecystitis symptoms.
The AXIOS Stent and Delivery System is currently being sold in Europe for use in pancreatic pseudocysts. The AXIOS Stent is an investigational device (limited by federal law to investigational use) and is not commercially available in the United States. An Investigational Device Exemption Study is being conducted to determine if the stent can safely and effectively treat pancreatic pseudocysts.
About Xlumena, Inc.
Xlumena, Inc. is the leader in the development of image-guided therapeutic endoscopy products, specializing in advanced implants and devices for therapeutic endoscopists. Collaborating with top physicians in the field, Xlumena focuses on technologies that advance therapy to the next level. These innovations may enable numerous minimally invasive transenteric therapeutic interventions, helping transform complex surgeries into lower cost and less complicated outpatient procedures.
Xlumena and AXIOS are trademarks of Xlumena, Inc.
SOURCE Xlumena, Inc.
CONTACT: Xlumena, Inc., +1-650-961-9900, info@xlumena.com

Monday, May 14, 2012

Lilly Oncology to present data from 25+ studies at ASCO


Lilly Oncology to Highlight Final Results for Phase III Study in Most Common Form of Lung Cancer

PARAMOUNT Study One of More than 25 Lilly Oncology Studies at Key Cancer Meeting

Full press release follows.

SOURCE: Eli Lilly

INDIANAPOLIS, May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from more than 25 studies at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1 – 5, 2012, including overall survival results from PARAMOUNT, a Phase III study of an ALIMTA® (pemetrexed for injection)-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer. Lilly presented progression-free survival data from PARAMOUNT at the 2011 ASCO meeting.
Other Lilly Oncology research being presented at ASCO will include additional clinical data on ALIMTA.
ALIMTA Studies:
  • Abstract # LBA7507: Oral Abstract Session: Monday, June 4, 2012; 5:15 PM – 5:30 PM
    • PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed plus best supportive care versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer
    • Author/Speaker: Luis Paz-Ares
    • Location: E Hall D2
  • Abstract # 7002: Oral Abstract Session: Monday, June 4, 2012; 8:30 AM – 8:45 AM
    • Phase II Study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIA/B non-small cell lung cancer
    • Author/Speaker: Hak Choy
    • Location: E Hall D2
P-LLY
This press release contains forward-looking statements about the potential of ALIMTA and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the product will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
SOURCE Eli Lilly and Company
CONTACT: Amy Sousa (Lilly), Office: +1-317-276-8478, Mobile: +1-317-997-1481; Neil Hochman (TogoRun), Office: +1-212-453-2067, Mobile: +1-516-784-9089
Related Links
IMAGELilly Oncology to Highlight Final Results for Phase III Study in Most Common Form of Lung Cancer
To see more releases from Eli Lilly and Company, Click Here
This company's web site http://www.lilly.com

Friday, April 27, 2012

Study: New Tx Options for Pediatric Neuroblastoma


Study presents potential new treatment options for pediatric neuroblastoma patients.

Full press release follows.
SOURCE: Texas Children's Hospital
HOUSTON, April 27, 2012 /PRNewswire-USNewswire/ -- A nationwide study led by Dr. Jed Nuchtern, chief of the division of pediatric surgery at Texas Children's Hospital, a pediatric surgeon with Texas Children's Cancer Center and professor of surgery at Baylor College of Medicine, found that the majority of infants with a particular form of neuroblastoma – a childhood tumor that often requires intensive chemotherapy and surgery – excel in their overall progress and survival when the tumor is monitored without surgical resection.
The results of the study will be presented at the American Surgical Association's 132nd annual meeting being held in San Francisco from April 26 to 28.
In this 10-year study, surgeons and oncologists who identified babies less than 6 months of age with a small tumor suggestive of neuroblastoma were given the option of immediate surgery or monitoring the baby carefully via ultrasound and urine tests. Overall, 87 babies who had tumors found either prenatally or before 6 months of age were entered into the study.
Of 87 babies, only four underwent surgery immediately – all of whom did well – while 83 were followed carefully for at least 15 months. Of the group that was followed, 16 children had surgery due to changes on one of the screening studies with eight found to have stage one neuroblastoma and only two with higher stages. There were no tumors that required additional intensive chemotherapy. 
Most importantly, the three-year overall survival for the 83 babies who were followed by observation was 100 percent with median follow-up now of three years.  Overall, 81 percent of these young babies on the observation arm were spared the need for surgery. The results of this study reveal that it is safe to carefully observe babies – specifically infants less than 6 months of age – who have a special, small isolated neuroblastoma tumor. 
The investigators are now planning a study that will expand to include patients who are 1 years old at diagnosis and who have larger neuroblastoma tumors. The study was sponsored by the Children's Oncology Group and included participation by more than 100 physicians from more than 75 pediatric programs across the United States and Canada, including Texas Children's Cancer Center.
About Texas Children's Hospital
Texas Children's Hospital, a not-for-profit organization, is committed to creating a community of healthy children through excellence in patient care, education and research. Consistently ranked among the top children's hospitals in the nation, Texas Children's has recognized Centers of Excellence in multiple pediatric subspecialties including the Cancer and Heart Centers, and operates the largest primary pediatric care network in the country. Texas Children's is completing a $1.5 billion expansion, which includes the Jan and Dan Duncan Neurological Research Institute; Texas Children's Pavilion for Women, a comprehensive obstetrics/gynecology facility focusing on high-risk births; and Texas Children's Hospital West Campus, a community hospital in suburban West Houston.  For more information on Texas Children's, go to www.texaschildrens.org. Get the latest news from Texas Children's by visiting the online newsroom and on Twitter at twitter.com/texaschildrens.
Contact: Elizabeth Shackouls
832-824-2108
ehshacko@texaschildrens.org 
SOURCE Texas Children's Hospital

Non-Invasive MicroPulse Therapy for glaucoma


IRIDEX makes peripheral devices and laser systems used to treat serious eye conditions including the three major causes of blindness: glaucoma, macular degeneration, and diabetic retinopathy. The firm is now launching its non-invasive MicroPulse Therapy for glaucoma.

Full press release follows.
SOURCE: IRIDEX Corporation

IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma

Tissue-Sparing, Repeatable MicroPulse Laser Trabeculoplasty (MLT) Extends Versatility of IRIDEX Green (IQ 532) Laser

MOUNTAIN VIEW, Calif., April 27, 2012 /PRNewswire/ -- IRIDEX Corporation today announced the launch of a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse™ technology.  The new glaucoma therapy, a tissue-sparing, repeatable therapy called MicroPulse Laser Trabeculoplasty (MLT), was introduced by IRIDEX at the recent American Society of Cataract and Refractive Surgery (ASCRS).
Glaucoma is the leading cause of adult irreversible blindness. It is estimated that more than 4 million people in the US and approximately 60 million people worldwide are afflicted with the disease today.
MLT was first introduced by IRIDEX in its infrared laser platforms, but recent technology advancements have now made it available with the IRIDEX green laser system (IQ 532), our most versatile and highest selling laser used by the broadest group of ophthalmologists. The unique ability of the IQ 532 to offer tissue-sparing repeatable therapies for both glaucoma and retinal diseases represents a market breakthrough as well as providing ophthalmologists a very high return on their capital investment, said Dr.Dominik Beck, IRIDEX President and CEO.
David Gossage, M.D., medical director of the Gossage Eye Institute, noted that the addition of the MicroPulse module to the IQ 532 system makes it a valid option for a much broader patient population than has historically been the case.
"Compared to other lasers used for the treatment of glaucoma, the IQ 532 with the MicroPulse module offers greater versatility because it can also be used for a range of other conditions including diabetic macular edema, proliferative diabetic retinopathy, and retinal tears," Dr. Gossage said.  "I'm comfortable offering MLT to glaucoma patients as a first-line option because of its potential to reduce intraocular pressure without causing tissue damage."
MLT produces laser pulses at very short durations to create a therapeutic response of lowering the intra-ocular pressure of a glaucoma patient without thermal damage. 
About MicroPulse Technology
MicroPulse is a tissue-sparing laser delivery therapy that works by electronically "chopping" the laser emission into trains of microsecond pulses. This enhances the physician's ability to more precisely control the laser effects on target tissues, offering the potential for ocular treatment with less collateral effects than conventional laser treatments.
 About IRIDEX
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology and otolaryngology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into 107 countries. For further information, visit the Company's website at http://www.iridex.com/.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the our growth strategy, the addressable market of our products and MicroPulse laser therapy.  These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors.  Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q which are filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
SOURCE IRIDEX Corporation
CONTACT: Company, Jim Mackaness, Chief Financial Officer, +1-650-940-4700, Investors, Matt Clawson, Allen & Caron, +1-949-474-4300, matt@allencaron.com
Web Site: http://www.iridex.com 

Thursday, April 26, 2012

Oncology News: FDA Advisory Committee to review NDA for carfilzomib


Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma.

Full press release follows.
SOURCE: Onyx Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, April 26, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the company's new drug application (NDA) for carfilzomib for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies. ODAC will review carfilzomib at its meeting on June 20, 2012. The Prescription Drug User Fee Act (PDUFA) date for completion of review by the FDA is July 27, 2012.
"Multiple myeloma is a deadly disease for which there are no cures, and we are committed to bringing carfilzomib to patients as quickly as possible," said Ted W. Love, M.D., Executive Vice President, Research and Development and Technical Operations at Onyx Pharmaceuticals. "Our team looks forward to discussing the potential efficacy benefit and safety profile of carfilzomib with the advisory committee and will continue to work closely with the FDA during its review."
About Oncologic Drugs Advisory Committee The ODAC reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cancer and makes recommendations to FDA. 
About Multiple MyelomaMultiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. In the United States, more than 50,000 people are living with multiple myeloma and approximately 20,000 new cases are diagnosed annually.(i) Worldwide, more than 180,000 people are living with multiple myeloma and approximately 86,000 new cases are diagnosed annually.(ii)
About Onyx Pharmaceuticals, Inc.Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer and other serious diseases. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx.com.
Forward-Looking StatementsThis news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, the expanded access program, safety, regulatory processes, commercialization efforts or commercial potential of carfilzomib.  These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the submission, review, potential approval of the NDA, development and commercialization of pharmaceutical products. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release.  Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

(i) National Cancer Institute, Surveillance Epidemiology and End Results, 2007 Facts and Figures
(ii) International Agency for Research on Cancer, GLOBOCAN 2002 database
SOURCE Onyx Pharmaceuticals, Inc.
CONTACT: Investors, Amy Figueroa, Senior Director, Investor Relations, +1-650-266-2398, or Media, Lori Melancon, Senior Director, Corporate Communications, +1-650-266-2394, both of Onyx Pharmaceuticals, Inc.
Web Site: http://www.onyx.com 

Wednesday, April 25, 2012

Organ transplant news, kidney transplanted twice in 2 weeks


Kidney Transplanted Twice in Two Weeks.

Full press release follows.
SOURCE: Northwestern Memorial Hospital
Transplant recipient donates kidney after disease threatens the organ; re-implantation reverses damage and allows another patient to thrive
CHICAGO, April 25, 2012 /PRNewswire-USNewswire/ -- For the first time, a kidney that had been donated to a patient in need was removed and implanted into a new patient, the third individual to have the organ, after it failed in the first transplant recipient.  Ray Fearing, a 27-year-old Arlington Heights resident received the organ from his sister, Cera, after a long battle with focal segmental glomerulosclerosis (FSGS), a disease in which scar tissue develops on the part of the kidney that filters waste out of the blood, ultimately causing kidney failure.  When signs of his illness reoccurred just days after he received the organ and posed life-threatening symptoms, doctors informed Fearing that they would have no choice but to remove the failing kidney.  They also informed Fearing that he could potentially save someone else's life by donating the organ and allowing doctors to re-implant it into another patient in need of transplant, something that had never successfully been done before with a kidney. 
"In over 50 percent of cases, transplant does not stop the process of FSGS. When post surgery tests indicated that Ray was at risk of developing life-threatening conditions due to the reoccurrence of the disease, we had to remove the kidney before he deteriorated.  The kidney however was still a relatively healthy, viable organ that could be transplanted into someone else without FSGS," explained Lorenzo Gallon, MD, transplant nephrologist and medical director of the kidney transplant program Northwestern Memorial Hospital and associate professor of medicine and surgery at Northwestern University Feinberg School of Medicine.
Northwestern Medicine® experts and members of the medical ethics committee reviewed the proposed procedure and evaluated the decision prior to re-implanting the organ.  The group discussed potential risks, which included the possibility that the kidney would fail to recover from its current level of minor damage due to its short exposure to FSGS while implanted in Fearing, thus failing to function properly in a new patient. 
"After numerous discussions to carefully consider this first-ever procedure, we presented Ray with the option to donate his kidney to someone on the national kidney waiting list rather than discarding it," said Gallon.
Fearing did not hesitate when he found out he could help someone in need like himself. Two weeks after receiving his kidney transplant, he donated his kidney to 67-year-old surgeon and father of five, Erwin Gomez.
The organ regained function almost immediately after re-transplantation and just eight days after transplantation, tests showed a reversal of the damage caused by the FSGS in Fearing's body. 
"This is a ground-breaking medical moment because it suggests that it is possible to reverse the damage done to a kidney as a result of FSGS after it is re-transplanted into a body with a healthy circulatory system," said Joseph Leventhal, MD, PhD, transplant surgeon at Northwestern Memorial Hospital and associate professor of surgery and director of kidney and pancreas transplantation at Northwestern University Feinberg School of Medicine. "Not only did we save a viable organ from being discarded, we also made significant strides in better understanding the cause of FSGS, which has been relatively unknown, so we can better treat the disease in the future.  This proves that when an organ fails in one body, it may thrive in another."
This innovative idea and resulting discovery is featured in the April 26 issue of the New England Journal of Medicine.
Fearing is back on dialysis to control his FSGS and is hopeful he will receive another kidney transplant in the future.
"It may not have been my time, but I am grateful that I was able to help another patient," said Fearing.  "My day will come."
Northwestern Medicine is the shared vision that joins Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine in a collaborative effort to transform medicine through quality healthcare, academic excellence and scientific discovery.  To learn more aboutNorthwestern's transplant program, visit the Kovler Organ Transplantation Center online, or call 312-695-0828.
About Northwestern Memorial HealthCareNorthwestern Memorial HealthCare is the parent of Chicago's Northwestern Memorial Hospital, an 894-bed academic medical center hospital and Northwestern Lake Forest Hospital, a 205-bed community hospital located in Lake Forest, Illinois. 
About Northwestern Memorial HospitalNorthwestern Memorial is one of the country's premier academic medical center hospitals and is the primary teaching hospital of the Northwestern University Feinberg School of Medicine.  Along with its Prentice Women's Hospital and Stone Institute of Psychiatry, the hospital comprises 894 beds, 1,705 affiliated physicians and 6,769 employees.  Northwestern Memorial is recognized for providing exemplary patient care and state-of-the art advancements in the areas of cardiovascular care; women's health; oncology; neurology and neurosurgery; solid organ and soft tissue transplants and orthopaedics.
Northwestern Memorial possesses nursing Magnet Status, the nation's highest recognition for patient care and nursing excellence.  It is also listed in 13 clinical specialties in U.S. News & World Report's2011 "America's Best Hospitals" guide and ranks No. 1 in Chicago in the 2011 U.S. News & World ReportBest Hospitals metro area rankings. For 12 years running, Northwestern Memorial has been rated among the "100 Best Companies for Working Mothers" guide by Working Mother magazine. The hospital is a recipient of the prestigious National Quality Health Care Award and has been chosen by Chicagoans as the Consumer Choice according to the National Research Corporation's annual survey for 13 years. 



SOURCE Northwestern Memorial Hospital
 CONTACT: Colleen Sheehan, +1-312-926-0755, csheehan@nmh.org
Web Site: http://www.nmh.org 

Tuesday, April 24, 2012

Successful Completion of First Cohort in Lung Cancer Trial


Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center

Demonstrates Positive Initial Imaging Results; Additional Clinical Results Expected by Mid-2012.

Full press release is below. 
Source: Novelos Therapeutics, Inc.
MADISON, Wis., April 24, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that the University of Wisconsin Carbone Cancer Center, a leading oncology research institution, has successfully completed the first cohort in a Phase 1-2 positron emission tomography (PET) imaging trial of I-124-CLR1404 (LIGHT), a cancer-targeted PET imaging agent, in patients with advanced non-small cell lung cancer (NSCLC).  The first cohort comprised three patients dosed with LIGHT at 5 mCi. Details of the trial design are available at www.clinicaltrials.gov ID: NCT00582283, or at www.novelos.com in the "Clinical Trials" section. Anne M. Traynor, M.D., is the trial's principal investigator. Detailed trial results are expected to be presented at a scientific venue at a later date.
"The preliminary results from the first cohort are encouraging. We see strong uptake of LIGHT in cancerous tumors against very low background and have not observed any adverse safety signals," said Dr. Traynor. "Although still early and in a small number of subjects, there is some suggestion that LIGHT imaging was more tumor-selective than the comparator modality 18F-fluorodeoxyglucose (18F-FDG) PET."
"Having observed initial cancer-specific uptake with LIGHT at 5 mCi in NSCLC patients, we now look forward to evaluating the next dose level in this indication," said Kim Hawkins, Vice President of Clinical Development of Novelos. "The protocol was prospectively designed to dose three patients at 3 mCi in the next cohort, as we seek to identify a minimally effective dose, and we look forward to obtaining these results in a few months."
"We are very pleased with the positive initial LIGHT imaging data in lung cancer patients obtained to date, and with our collaboration with the UW Carbone Cancer Center," said Harry Palmin, President and CEO of Novelos. "We believe these data begin to establish proof-of-concept for LIGHT as a PET imaging agent for NSCLC, could advance our partnering discussions and could be used to calculate effective doses for Phase 2 clinical trials of I-131-CLR1404 (HOT). HOT is our chemically identical small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells."
About LIGHTLIGHT is a small molecule imaging agent that we believe has first-in-class potential for selective detection of tumors and metastases in a broad range of cancers. LIGHT is comprised of a small, non-pharmacological quantity of CLR1404 (COLD, acting as a cancer-targeted delivery and retention vehicle) labeled with the short-lived radioisotope, iodine-124, a new PET imaging isotope. PET imaging used in conjunction with CT scanning has now become the imaging method of choice in oncology. In studies to date, LIGHT selectively illuminated malignant tumors in 52 of 54 animal models of cancer, demonstrating broad-spectrum, cancer-selective uptake and retention.  Investigator-sponsored Phase 1-2 trials of LIGHT as a PET imaging agent are ongoing. The trials include lung cancer, brain cancer and, starting in the second quarter of 2012, other solid tumors. These human trials, if successful, will serve three important purposes. First, they would provide proof-of-concept for LIGHT itself as a PET imaging agent with the potential to supplant the current "gold standard" agent, 18-fluoro-deoxyglucose (FDG), due to what we believe to be LIGHT's superior cancer-specificity and more favorable logistics of clinical use. Second, favorable results would advance partnering discussions for LIGHT. Third, tumor uptake data will accelerate clinical development of HOT by predicting efficacy and enabling calculation of efficacious doses of HOT for Phase 2 trials.
About the UW Carbone Cancer Center in Madison The University of Wisconsin Carbone Cancer Center (UWCCC) is recognized throughout the nation as one of the leading innovators in cancer research, quality patient care and active community involvement. It is the only comprehensive cancer center, as designated by the National Cancer Institute, in Wisconsin. An integral part of the UW School of Medicine and Public Health, the UWCCC unites physicians and scientists who work together in translating discoveries from research laboratories into new treatments that benefit cancer patients. To learn more about clinical studies and other initiatives, visitwww.uwhealth.org/uw-carbone-cancer-center/for-researchers/uwccc/28373.
About Novelos Therapeutics, Inc.We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer. Our three cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells. Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. I-124-CLR1404 (LIGHT) is a small-molecule cancer-targeted PET imaging agent. We believe LIGHT has first-in-class potential and Phase 1-2 clinical trials are ongoing. I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. We believe HOT also has first-in-class potential. HOT Phase 1b dose-escalation trial is ongoing and we expect HOT to enter Phase 2 trials in the first quarter of 2013 as a monotherapy for solid tumors with significant unmet medical need, subject to additional funding. CLR1404 (COLD), a pre-clinical cancer-targeted non-radioactive chemotherapy, works primarily through Akt inhibition. Together, we believe our compounds are able to "find, treat and follow" cancer anywhere in the body in a novel, effective and highly selective way. For additional information please visit www.novelos.com.
INVESTOR CONTACTS

J. Patrick Genn, Vice President of IR
Anne Marie Fields, Senior Vice President
Novelos Therapeutics, Inc.
LHA
Ph: (858) 775-7456
Ph: (212) 838-3777
Email: afields@lhai.com, @LHA_IR_PR
Novelos Therapeutics, Inc.
Madison, WI                Boston, MA
This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our  pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.
SOURCE Novelos Therapeutics, Inc.